Drug Profile
Research programme: small molecule therapeutics - AstraZeneca/ChemBridge Corporation
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; ChemBridge Corporation
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Russia
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
- 24 Sep 2008 AstraZeneca enters into a new research collaboration with ChemBridge